Category Archives: Immunology

Immunology

Immunology as The Ultimate Riddle A Conversation with an Immunologist – BioSpace

Immunology is one of the most complex fields of life science to study. Thousands of scientists utilize their expertise in biology to focus on autoimmune diseases, cancer, immunodeficiencies and other immune disorders to help patients and cure diseases. We recently interviewed Marianne Stanford, Ph.D., who serves as Vice President of Research and Development at IMV, Inc. Stanford shared her thoughts on the field and the career path of an immunologist. If you are interested in immunology, hearing from a leader in industry and academia is beneficial!

I was born and raised in Newfoundland, a small province on the eastern coast of Canada. Growing up, I always saw myself as someone keenly focused on science and yet the only career option I saw for myself was as a veterinarian. Once I entered university, I began to see the breadth of career paths you could do in science. I tried several, including working as a summer field biologist, and quickly learned that working in the field was not for me. That lead me to work in the lab. Fundamentally, looking back, Ive always been someone asking questions this fundamentally led me to be a scientist.

Immunology is the study of our immune system. The immune system is in some ways the ultimate riddle in some ways so simple and yet ridiculously complex. The job of the immune system is to determine what is self and protect it from invaders. But the way in which it does this is something we learn more about every day. For that reason, it is a great (and yet sometime very frustrating) field of study!

I think that whats really interesting about studying the immune system is that everyone feels that they have a good handle on what their immune system is and how it works. We understand that our body fights disease and that vaccines help protect us. However, once you begin to study the immune system in depth, you realize that there are so many things that we do not fully understand and that harnessing the immune system is incredibly difficult to do in the clinic.

There are a couple of really exciting new opportunities that have emerged in immunology in recent years. First and foremost, as our understanding of the checks and balances in the immune system have allowed us to advance new therapies that act directly on it to impact disease. The most obvious one is the advances of immunotherapy in cancer, whereby we manipulate and stimulate the immune system to help fight diseases like cancer. This has opened a huge opportunity to treat many diseases with our own immune system, hopefully being more effective with fewer side effects. The second has been the understanding of the microbiome, or how the microbes that make up our bodies have a direct impact on our immune system. This study may change how we think of this interaction and is very exciting to follow.

I think the opportunity to be on the cutting edge of new treatments for diseases like cancer are so gratifying. There are also many opportunities for collaboration and working with other great scientists on complex questions. This is an awesome way to work.

I think like any field, to be at your best you need to find the right opportunities for mentorship and training. Ive been very lucky to work with world-class scientists during my training and that has really allowed me to be successful.

Keep asking questions and never give up. Surround yourself with people who are passionate and as focused on mentorship as they are in science.

Porschia Parker-Griffin is a Certified Coach, Professional Resume Writer, and Founder of Fly High Coaching. (https://www.fly-highcoaching.com) She empowers ambitious professionals and motivated executives to add $10K on average to their salaries.

Marianne Stanford, PhD. is Vice President of Research and Development at IMV Inc., overseeing all preclinical research activities and clinical immunology assessment of cancer immunotherapies and infectious disease vaccines. In addition, she serves as an Adjunct Professor in Microbiology and Immunology at Dalhousie University. Dr. Stanford received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University.

Read more:
Immunology as The Ultimate Riddle A Conversation with an Immunologist - BioSpace

Immunology

Immunology Market ? What Factors Will Drive The Market In Upcoming Years And How It Is Going To Impact On Global Industry | (2020-2026) – The Daily…

DataIntelo has published a latest market research report on Global Immunology Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The published report explains about the current supply and demand scenario and presents the future outlook of the market in a detailed manner. DataIntelo has applied a robust market research methodology to bestow the new entrants and emerging players with 360 wide-view analysis on the latest advancements and their impacts on the market. It has congregated massive amount of data on the key segments of the market in an easy to understand format. The research report has laid out the numbers and figures in a comprehensive manner with the help of graphical and pictorial representation which embodies more clarity on the market.

You can buy this complete report @ https://dataintelo.com/checkout/?reportId=80796

Report Covers Impacts of COVID-19 to the market.

The on-going pandemic has overhauled various facets of the market. This research report provides the financial impacts and market disturbance on the Immunology market. It also includes analysis on the potential lucrative opportunities and challenges in the foreseeable future. DataIntelo has interviewed various delegates of the industry and got involved in the primary and secondary research to confer the clients with information and strategies to fight against the market challenges amidst and after COVID-19 pandemic.

Market Segmentation:

Few of the companies that are covered in the report.

AbbVieAmgenF. Hoffmann-La RocheJohnson & JohnsonBionor PharmaCelgeneCellectar BioscienceseFFECTOR Therapeutics

Note: Additional companies can be included in the list upon the request.

By Product Type:

Immuno BoostersImmunosuppressants

By Applications:

Autoimmune DiseasesOncologyOrgan TransplantationOthers

By Geographical Location:Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

Get A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=80796

The research report provides a detailed analysis of the prominent player in the market, products, applications, and regional analysis which also include impacts of government policies in the market. Moreover, you can sign up for the yearly updates on the Immunology market.

7 Reasons for Buying Immunology Market Report

If you have any query regarding the report, ask our experts: @ https://dataintelo.com/enquiry-before-buying/?reportId=80796

Below is the TOC of the report:

Immunology Supply Chain Analysis

Immunology Pricing Analysis

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://dataintelo.com

Original post:
Immunology Market ? What Factors Will Drive The Market In Upcoming Years And How It Is Going To Impact On Global Industry | (2020-2026) - The Daily...

Immunology

Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe immune-mediated diseases, will participate in the upcoming Immunology and Inflammation Virtual Summit hosted by Stifel. Dr. Edward Driggers, Rheoss Chief Technology Officer, will participate in a panel discussion entitled The Key To Unlocking Immune Cell Function at 2:00 PM EDT on Thursday, October 1st, 2020.

A live webcast of the event will be available here: https://wsw.com/webcast/stifel23/panel6/2330952.

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple omic datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit http://www.rheosrx.com.

Continued here:
Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit - Business Wire

Immunology

Sanofi’s Dupixent focus will pay off to the tune of $12.5B in peak sales: analysts – FiercePharma

Since taking over at Sanofi a year ago, CEO Paul Hudson has made immunology blockbuster Dupixent one of his top prioritiesand set some lofty sales goals, too.

The company's focus on the drug is already paying off. In fact, it's set to reach $12.5 billion in peak sales, Jefferies analysts wrote, or about 10.8 billion, beating Hudson's own 10 billion goal.

As of the second quarter, Dupixent is generating about $1 billion every three months. Looking forward, Jefferies figures the med can grow based on further penetration into the atopic dermatitis marketwhere its a market leaderand by posting gains in asthma and numerous other indications, the analysts wrote in a Tuesday note to clients.

Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

In atopic dermatitis, the Jefferies analysts predict the meds sales could almost double from 3 billion to nearly 6 billion in 2028. That expectation is based on a survey of 25 dermatologists in the U.S., who expect more patients to get treatment over the coming three years.

RELATED: Dupixent sales of 10B? We're on track, Sanofi CEO Hudson says

In asthma, the analysts predict Dupixents sales of around 460 million now will reach 2.9 billion by 2028, based on an assumption that 30% of eligible patients will be treated with a biologic. Meanwhile, Dupixent is already approved in chronic rhinosinusitis with nasal polyps, and the med is in late-stage testing for several other diseases. The analysts predict 2.2 billion in peak sales from uses other than asthma and atopic dermatitis.

Altogether, the analysts expect 10.8 billion in peak sales from Dupixent, above consensus estimates of 9.7 billion.

After taking the reins at Sanofi last September, Hudson said new indications and launches in new countries could fuel Dupixent to more than 10 billion in peak sales. Aside from his focus on Dupixent, Hudson launched a cost-cutting initiative aimed at saving 2 billion by 2022.

RELATED: Sanofi touts Dupixent's pandemic 'resilience' as cost cuts add up

Further, the drugmaker set out to focus its R&D engine only on first-in-class" or best-in-class" drugs, as Hudson puts it. As Sanofi works to advance internal research, the company has been busy scouting and striking deals, recently with its $3.7 billion Principia Biopharma buyout.

While Dupixent will be the company's "key growth driver" moving forward, Jefferies analysts are also optimistic about the company's flu vaccines, its pipeline and its ability to cut costs. From an investment standpoint, they see Sanofi as the most compelling European large pharma company right now.

Link:
Sanofi's Dupixent focus will pay off to the tune of $12.5B in peak sales: analysts - FiercePharma

Immunology

UGA leads study on COVID-19 post-infection immunity – The Albany Herald

ATHENS A key question surrounding COVID-19 is if people who have had the virus gain some degree of long-term immunity. Ted Ross is leading a nationwide study to examine this pressing question. Ross is director of the University of Georgias Center for Vaccines and Immunology and professor of infectious diseases in the College of Veterinary Medicine.

The bodys response to every infection is unique, Ross said. In this study, we hope to determine how the body fights this novel virus and what, if any, protection the body develops following infection.

The team also hopes to examine immunological, demographic and medical risk factors and the part they play in recovery and infection outcome. Using blood draws and saliva samples, the researchers will monitor participants over the course of 24 months. The project, called SPARTA (SARS SeroPrevalence and Respiratory Tract Assessment), is funded by the NIH National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

In Athens and Augusta, the study will establish and follow participants at higher risk of exposure to the SARS-CoV-2 virus, including local health care and emergency services providers, as well as faculty, staff and students at UGA. The group will total about 3,000 participants between 18 and 85 years of age and at least 50% of the participants will be members of minority populations, which have been impacted by COVID-19 at a higher rate than other groups.

UGA will participate with other teams of investigators from universities and health care providers around the country including Augusta University Medical Center, Mt. Sinai Medical Center in New York City, University of Chicago, University of Miami, University of Michigan at Ann Arbor, University of California at Los Angeles Harbor Medical Center, Washington University Medical Center in St. Louis, and St. Jude Childrens Research Hospital in Memphis.

The list is expected to grow as more institutions join the project. The data collected from these locations will be aggregated and compared for a nationwide view of immunity and recovery from COVID-19.

Follow this link:
UGA leads study on COVID-19 post-infection immunity - The Albany Herald

Immunology

FlowMetric Life Sciences, Inc. and Penn State University announce a Collaboration Study on University and Community COVID-19 Antibody Testing -…

DOYLESTOWN, Pa., Sept. 29, 2020 /PRNewswire/ --FlowMetric Life Sciences, Inc., a global leader in immunology testing services, and the Huck Institutes of the Life Sciences at Penn State University announce the creation of a long-term collaboration study assessing the impact on the Centre County community's potential exposure to COVID-19 by Penn State University students returning to campus.

Together with Penn State's Center for Clinical Research, the Huck Institutes will collect thousands of blood samples from Penn State students and members of the Centre County community at the beginning and end of each academic semester for four academic semesters.

The samples will be sent to FlowMetric, a GLP-compliant, CLIA-certified, High Complexity clinical laboratory located in Doylestown, PA for analysis. FlowMetric is providing validated serology testing under the FDA's Emergency Use Authorization mandate. The test detects the presence of anti-SARS-CoV-2 (COVID-19) IgG antibodies and will identify individuals who have mounted an immune response following viral exposure, even if they are asymptomatic.

Andrew Read, the project leader with Huck Institutes, said "COVID is a serious challenge that needs local and global focus. We are absolutely delighted to to be partnering with a dynamic and forward-looking Pennsylvanian biotech company on this study. We call it 'Data 4 Action' because we want to make a difference. It is clear that FlowMetric does too".

"This project is a natural extension to the FlowMetric vision of improving the lives of individuals through our cutting-edge science and expertise in immune monitoring" said Renold Capocasale, CEO & Founder of FlowMetric Life Sciences. "We are honored to be partnering with Penn State University, a world-renown center of research excellence" he added.

The results of the study will be reported to the PA Department of Health as part of ongoing surveillance in response to the COVID-19 pandemic. Researchers at Penn State's Institute for Social Sciences will also be collecting questionnaire data on other impacts of COVID including economic and other health impacts. Here is a link to the study site: https://covid-19.ssri.psu.edu/data4action.

About FlowMetric Life Sciences, Inc.With laboratories in Doylestown, PA (USA) and Bresso, Italy, FlowMetric Life Sciences is a globally recognized Contract Research Organization providing World-Class Analytical services, Flow Cytometry and Single-Cell Proteomics capabilities, and expertise in Immunology, Cellular and Gene Therapy, Oncology, and Infectious Diseases, supporting many of the world's largest Pharmaceutical and Biotech companies.

About the Huck Institutes of the Life Sciences at Penn State UniversityThe Huck Institutes were established in 1996 to enhance and facilitate excellence in interdisciplinary research and training in the life sciences across Penn State. We facilitate new initiatives and insights by seeding emerging fields and providing leadership in interdisciplinary graduate education.

SOURCE FlowMetric

flowmetric.com

View original post here:
FlowMetric Life Sciences, Inc. and Penn State University announce a Collaboration Study on University and Community COVID-19 Antibody Testing -...

Immunology

New genetic knowledge on the causes of severe COVID-19 – Newswise

Newswise Worldwide, otherwise healthy adolescents and young people without underlying conditions are sometimes severely affected by COVID-19, with the viral infection in the worst cases quickly becoming life-threatening. But why is this happening?

A world-wide consortium of researchers is determined to investigate this - and they have now made so much progress thatSciencehas just published two scientific articles describing some of their results.

Professor Trine Mogensen from the Department of Biomedicine at Aarhus University is co-author on the two research articles inScience. She conducts research into rare immunodeficiencies that lead to increased susceptibility to viral infections and, together with her research group, participates in the steering committee of the research consortium Covid human genetic effort (covidhge) as the only Danish representativ.

She explains that in the vast majority of people, infection with the COVID-19 causing coronavirus leads to an anti-viral response in which interferon plays a crucial role. Interferon is an importantimmune signaling hormone that slows the division of the virus and prevents it from penetrating the surrounding cells. In the event of a viral infection, the body normally quickly begins producing interferon, and the virus can be brought under control withing a few hours. In popular terms, interferon is our first safeguard against an infection.

"However, if there are defects in the interferon signalling pathways, there is nothing to inhibit the virus dividing, and while the coronavirus usually remains in the cells in the throat, it can in this case also infect other parts of the body such as the lungs, kidneys and perhaps even the brain," explains Trine Mogensen, who also is Medical Specialist at the Department of Infectious Diseases, Aarhus University Hospital, Denmark

Genetic and immunological analyses of blood samples from 650 patients from all over the world with severe COVID-19 show that some of these patients have an inherited immunodeficiency which leads to the anti-viral interferon either not being produced or not working on the body's cells. Blood samples from 1,226 healthy individuals have functioned as a control group - with all of the samples being taken prior to the COVID-19 pandemic.

The researchers have obtained consent to collect blood samples and carry out a genetic analysis from hospitalized and severely ill COVID-19 patients. From the blood samples, the researchers have purified immune cells from the 650 patients and subsequently infected these immune cells with coronavirus, which enabled them to ascertain that the immune system was not properly activated. In addition, a genetic sequencing of DNA from the 650 patients has been carried out, with some of this work being carried out at Aarhus University Hospital.

"Our DNA consists of approximately 20,000 genes, and we have found defects in thirteen different genes. This means that the proteins which the genes encode become defective and therefore cannot perform their role in the immune system. We're already aware of some of these genetic defects from patients affected by severe influenza, but some are new and specific to COVID-19," says Trine Mogensen.

The next task for the international research consortium is to translate - i.e. transfer - the basic immunological findings to the treatment of patients, and the first clinical trials are on the way. Medical doctors will be able to measure whether the patients have autoantibodies in their blood as these are relatively easy to measure, and if they are, they can be filtered from the blood. It will also be possible to screen for the thirteen critical genes identified and in this way have the ability to identify particularly vulnerable individuals. This group will then be able to receive preventative medical treatment and a vaccine once this is available.

"The goal is to prevent the very severe cases of COVID-19 with high mortality rates," summarizes Trine Mogensen, who is optimistic and hopes that the clinical trials will demonstrate positive results - perhaps already within a year.

She does not only base her optimism on the unique international collaboration which exists in the COVID Human Genetic Effort, as the international research consortium is named.

"I've never experienced anything like it before in my field of immunology and infectious diseases. We share knowledge and work together in a very altruistic spirit," she adds. The consortium comprises more than 250 researchers under the overall leadership of Professor Jean-Laurent Casanova from The Rockefeller University in the United States - with the professor also serving as an Honorary Skou professor at Aarhus University since 2019.

###

Read the original:
New genetic knowledge on the causes of severe COVID-19 - Newswise

Immunology

Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates – BioSpace

BOSTON, Sept. 29, 2020 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced it has raised $77 million in a Series B financing. The round was led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors.

"We are delighted to have ARCH Venture Partners lead this financing, and to welcome new investors into the condensate field," said Amir Nashat, managing partner of Polaris Partners and interim CEO of Dewpoint. "Our proprietary platform has already generated two significant external collaborations with Merck and Bayer, and today's announcement underscores the interest in biomolecular condensates among investors with a track record of backing groundbreaking science."

Dewpoint's proprietary condensates platform provides the ability to see and understand the complex interactions of biomolecular communitiesand to find drugs that intervene in entirely new ways. Dewpoint will use proceeds from this round to further develop its platform and identify additional compounds that modulate these condensates.

"Dewpoint is the international center of gravity for developing and translating condensate science into drugs," said Kristina Burow, managing director at ARCH Venture Partners. "The company is well positioned to leverage novel insights into fundamental biology and utilize this groundbreaking biology to create transformational therapeutics."

"The Dewpoint team is a unique combination of executives who have brought more than ten drugs to market and researchers who have spent the last several years defining the science of condensates," said Oleg Nodelman, founder and portfolio manager of EcoR1 Capital. "This collection of drug hunters is a powerful force."

In addition to announcing its Series B, Dewpoint today announced the addition of Giuseppe Ciaramella, Ph.D., to its Board of Directors. Ciaramella is president and chief scientific officer of Beam Therapeutics. Prior to Beam, Dr. Ciaramella served at Moderna, first as head of immunology and biotherapeutics, then as chief scientific officer of its infectious diseases division. Prior to Moderna, he held senior drug development roles at AstraZeneca, Boehringer Ingelheim, and Pfizer. Dr. Ciaramella holds a B.Sc. and Ph.D. in biochemistry and molecular biology from University College London.

Dewpoint's proprietary platform uses high-throughput methods to test libraries of potential drugs for the desired effect, identifying compounds that modulate biomolecular condensates in specific diseases of immediate interest to Dewpoint and its partners. Approaches to modulating condensates that may positively impact disease include dissolving or forming condensates, modulating the composition of condensates, stabilizing condensates, and selective drug delivery into condensates.

In July 2020, Dewpoint announced an exclusive collaboration with Merck (MSD) to leverage Dewpoint's proprietary biomolecular condensate platform for the development of a novel mechanism for the treatment of HIV. In November 2019, Dewpoint announced a collaboration with Bayer, combining the potential of Dewpoint's condensate platform with Bayer's small molecule compound library to develop new treatments for cardiovascular and gynecological diseases.

In addition to disease areas where Dewpoint has announced collaborations, the company is exploring potential therapeutic opportunities in oncology, neurodegeneration, metabolic disease, and immunology.

About Biomolecular Condensates Biomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders. The first condensates were observed more than 100 years ago. It is only in the last dozen years, though, that scientistsincluding Dewpoint founders Tony Hyman of the Max Planck Institute in Dresden and Rick Young of the Whitehead Institutehave begun to understand the dynamic nature and function of condensates. Dewpoint develops drugs that exploit this biology. Prior to the discovery of biomolecular condensate function, it was unknown how the right molecules could find each other at the right time to catalyze important processes in the crowded molecular environment of the cell.

About Dewpoint TherapeuticsDewpoint Therapeutics is the first to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases.

Learn more at dewpointx.com, and follow us on Twitter and LinkedIn.

Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.

View original content to download multimedia:http://www.prnewswire.com/news-releases/dewpoint-therapeutics-raises-77m-series-b-financing-to-advance-the-development-of-drugs-that-target-biomolecular-condensates-301139441.html

SOURCE Dewpoint Therapeutics

Originally posted here:
Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates - BioSpace

Immunology

Global Mice Model Market Research Report 2020: Increasing Implications of Mouse Clinical Trials (MCTs) for More Predictive Outcomes and Ongoing…

Dublin, Sept. 28, 2020 (GLOBE NEWSWIRE) -- The "Global Mice Model Market by Mice Type (Inbred, Knockout), Technology (CRISPR, TALEN, ZFN), Application (Oncology, Diabetes, Immunology), Service (Breeding, Cryopreservation, Genetic Testing), Care Products (Cages, Bedding, Feed), and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period.

The major factors driving the growth of this market are the Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing implications of mouse clinical trials (MCTs) for more predictive outcomes and ongoing innovations in mice models are driving the growth of the global mice model industry. However, Implementation of laws and regulations for animal protection and welfare has enforced restrictive practices and bans on the use of animals for different purposes that may restrict the growth of this market to a certain extent.

Asia Pacific: The fastest-growing region in the mice model market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

North America: The largest share of the drug discovery services market

North America, which includes the US and Canada, accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Mice Model Market Overview4.2 Asia-Pacific: Mice Model Market Share, by Mice Care Product and by Country (2019)4.3 Mice Model Market, by Mice Type4.4 Mice Model Market Share, by Service, 2020 Vs. 20254.5 Mice Model Market, by Application, 2020 Vs. 2025 (USD Million)

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Market Drivers5.2.1.1 Growing Usage of Mice Models in Virology and Infectious Diseases5.2.1.2 Increasing Implications of Mouse Clinical Trials (MCTS) for More Predictive Outcomes5.2.1.3 Increasing Demand for Personalized Medicine5.2.2 Restraints5.2.2.1 Regulations and Laws for the Ethical Use of Animals in Research5.2.3 Opportunities5.2.3.1 CRISPR Emerging as a Powerful Tool in Biomedical Research5.2.3.2 Rising Demand for Humanized Mice Models5.2.4 Challenges5.2.4.1 Development of Alternative Animal Testing Methods5.2.5 Threats5.2.5.1 Growing Use of Rat Models5.3 Impact of the COVID-19 Outbreak on the Growth of the Mice Model Market

6 Regulatory Assessment6.1 Introduction6.2 North America6.3 Europe6.4 China6.5 Japan6.6 India6.7 Australia6.8 Brazil

7 Clinical Studies Assessment7.1 Introduction7.2 Clinical Studies

8 Mice Model Market, by Mice Type8.1 Introduction8.2 Inbred Mice8.2.1 Increasing Applications of Inbred Mice Likely to Drive the Market8.3 Outbred Mice8.3.1 Genetic Diversity Offered by Outbred Mice to Boost the Market8.4 Genetically Engineered Mice8.4.1 Increasing Focus on Personalized Medicines to Drive Demand8.5 Hybrid/Congenic Mice8.5.1 Increasing Use of Congenic Mice in Biomedical Research Contributes to Market Growth8.6 Conditioned/Surgically Modified Mice8.6.1 Increasing Incidence of Metabolic Diseases to Drive the Market8.7 Spontaneous Mutant Mice8.7.1 Advancements in Biomedical Research and Increasing Applications to Boost Demand

9 Mice Model Market, by Service9.1 Introduction9.2 Breeding9.2.1 Growing Number of Mice Model Studies to Boost the Market9.3 Cryopreservation9.3.1 Need for Preservation of Novel Mice Models Likely to Drive the Market9.4 Quarantine9.4.1 Rising Demand for Germ-Free Mice to Boost Market9.5 Rederivation9.5.1 Stringent Quality Assurance Standards to Boost the Market9.6 Model In-Licensing9.6.1 Increasing Independent Research by Scientific Community Likely to Fuel Market Growth9.7 Genetic Testing9.7.1 Rising Demand for Transgenic Mice Likely to Drive the Market9.8 Other Services

10 Mice Model Market, by Technology10.1 Introduction10.2 CRISPR/Cas910.2.1 Advantages of CRISPR Likely to Boost Segment Growth10.3 Microinjection10.3.1 High Success Rate and Lack of Constraints to Propel Segment10.4 Embryonic Stem Cell Injection10.4.1 Growing Demand for Targeted Mice Models to Propel the Market10.5 Nuclear Transfer10.5.1 Potential to Produce Identical Mice is Likely to Drive Market Growth10.6 Other Technologies10.6.1 Sperm-Mediated Gene Transfer10.6.2 Virus/Vector-Mediated Gene Transfer10.6.3 Liposome-Mediated Dna and Electroporation of DNA10.6.4 Biolistics10.6.5 Talens and ZFNS

11 Mice Model Market, by Application11.1 Introduction11.2 Oncology Studies11.2.1 Increasing Implications of Mice Models in Study of Cancer to Drive the Market11.3 Immunology and Inflammation Studies11.3.1 Development of Advanced Models for Human Immunology Studies to Boost Market Growth11.4 Endocrine Metabolic Studies11.4.1 Growing Prevalence of Metabolic Disorders Likely to Drive the Market11.4.2 Diabetes Studies11.4.3 Other Endocrine Metabolic Studies11.5 Cardiovascular Studies11.5.1 Rising Burden of Cardiovascular Disorders Has Boosted Overall R&D Activity11.6 Central Nervous System (CNS) Studies11.6.1 Increasing Focus on Mice Model Development for CNS Disorders to Propel Market11.7 Genetic Studies11.7.1 Advancements in Gene Editing Techniques to Drive the Market11.8 Infectious Disease Studies11.8.1 Increasing Outbreaks of Infectious Diseases to Propel Drug Development Activities11.9 Other Disease Studies

12 Mice Model Market, by Mice Care Product12.1 Introduction12.2 Cages12.2.1 Development of Different Cage Systems to Drive the Market12.3 Feed12.3.1 Preference for Healthy and Powered Diet to Drive the Market12.4 Bedding12.4.1 Environmental Enrichment Strategy for Welfare of Laboratory Animals Likely to Boost Market Growth12.5 Other Mice Care Products

13 Mice Model Market, by Region

14 Competitive Landscape14.1 Introduction14.2 Market Ranking AnalysisFigure 23 Company Ranking in the Mice Model Market, 2019

15 Company Evaluation Matrix and Company Profiles15.1 Overview15.2 Mice Model Market: Company Evaluation Matrix15.2.1 Stars15.2.2 Emerging Leaders15.2.3 Pervasive Companies15.2.4 Participants15.3 Market Evaluation Framework15.4 Competitive Scenario15.4.1 Key Product Launches15.4.2 Key Acquisitions15.4.3 Key Collaborations15.4.4 Key Service Expansions15.5 Company Profiles15.5.1 Charles River Laboratories International15.5.2 The Jackson Laboratory15.5.3 Envigo15.5.4 Genoway15.5.5 Taconic Biosciences, Inc.15.5.6 Janvier Labs15.5.7 Harbour Biomed15.5.8 Trans Genic, Inc.15.5.9 Ingenious Targeting Laboratory15.5.10 Polygene15.5.11 GVK Bio15.5.12 Cyagen Biosciences15.5.13 Crown Bioscience Inc. (Subsidiary of JSR Corporation)15.5.14 Transcure Bioservices15.5.15 Ozgene Pty. Ltd.15.5.16 The Andersons, Inc.15.5.17 Fengshi Group15.5.18 Allentown, LLC15.5.19 Innovive15.5.20 Lab Products, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/2smp0w

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more from the original source:
Global Mice Model Market Research Report 2020: Increasing Implications of Mouse Clinical Trials (MCTs) for More Predictive Outcomes and Ongoing...

Immunology

The science and medicine of human immunology – Science Magazine

Immunology through a human lens

The coronavirus disease 2019 (COVID-19) pandemic has underscored the critical need to better understand the human immune system and how to unleash its power to develop vaccines and therapeutics. Much of our knowledge of the immune system has accrued from studies in mice, yet vaccines and drugs that work effectively in mice do not always translate into humans. Pulendran and Davis review recent technological advances that have facilitated the study of the immune system in humans. They discuss new insights and how these can affect the development of drugs and vaccines in the modern era.

Science, this issue p. eaay4014

The mammalian immune system is a remarkable sensory system for the detection and neutralization of pathogens. History is replete with the devastating effects of plagues, and the coronavirus disease 2019 (COVID-19) pandemic is a defining global health crisis of our time. Although the development of effective vaccines has saved many lives, the basic workings of the immune system are complex and require the development of animal models, such as inbred mice. Indeed, research in mice has been enormously productive, and the tremendous insights gleaned have resulted in many Nobel prizes and other accolades. However, past results are not necessarily a reliable guide to the future, and a notable limitation of animal models has been their failure to accurately model some human diseases and their inability to predict human immune responses in many cases. With regard to inbred mice, which have been the principal model of choice for immunology, this is likely due to the compromises that were necessary to create a more tractable and reproducible system for experimentation, such as genetic uniformity and lack of pathogen exposure, as well as the fact that mice are evolutionarily quite distinct. These considerations suggest that direct studies of the human immune system are likely to be extremely rewarding, both from a scientific and a medical perspective.

In the past decade there has been an explosion of new approaches and technologies to explore the human immune system with unprecedented precision. Insights into the human immune response to vaccination, cancers, and viral infections such as COVID-19 have come from high-throughput omics technologies that measure the behavior of genes, mRNA (single-cell transcriptomics), proteins (proteomics), metabolites (metabolomics), cells (mass cytometry), and epigenetic modifications (ATAC-seq), coupled with computational approaches.

Sydney Brenner remarked in 2008, We dont have to look for a model organism anymore. Because we are the model organisms. We propose that studying the immune system in humans, who are genetically diverse and afflicted by a multitude of diseases, offers both a direct link to medicine (i.e., translation) and the very real prospect of discovering fundamentally new human biology. New approaches and technology are now making this area much more approachable, but profiling immunity in humans is but the first step. Computational mining of the data and biological validation in animal models or human organoids are essential next steps, in an iterative cycle that seeks to bridge fundamental and applied science, as well as mouse and human immunology, in a seamless continuum of scientific discovery and translational medicine. This will represent a new paradigm for accelerating the development of vaccines and therapeutics.

Systems biology techniques can be used to probe the human immune response to viral infections and can define molecular signatures that predict disease severity and illuminate the underlying mechanisms of disease.

Although the development of effective vaccines has saved countless lives from infectious diseases, the basic workings of the human immune system are complex and have required the development of animal models, such as inbred mice, to define mechanisms of immunity. More recently, new strategies and technologies have been developed to directly explore the human immune system with unprecedented precision. We discuss how these approaches are advancing our mechanistic understanding of human immunology and are facilitating the development of vaccines and therapeutics for infection, autoimmune diseases, and cancer.

Read the original here:
The science and medicine of human immunology - Science Magazine